Drugs / Deferitrin
Deferitrin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00069862 | Sep 2003 → Nov 2005 | beta thalassemia | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deferitrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069862 ↗ |
| Known as | DEFERITRIN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL432481 ↗ |
| Known as | Deferitrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL432481 ↗ |
| Known as | Deferitrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL432481 ↗ |
| Known as | GT56-252 | “Deferitrin (GT56-252)” NCT00069862 ↗ |
| Modality | Small molecule | — CHEMBL432481 ↗ |
| Route | Oral | “deferitrin (GT56-252), an experimental oral iron chelator” NCT00069862 ↗ |